secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-08-17T23:59:59+00:00
Accession:  0001104659-21-106641
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data
-------------------------------------------------------------------------------

- Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.
- Cash and equivalents $56.7M at June 30, 2021, expected to fund operations into Q1 2023.
- ELX-02 Phase 2 CF monotherapy data on track for Q4 2021; combination arm with ivacaftor to start by end of 2021.
- ZKN-013 nominated as lead candidate for RDEB/JEB; IND-enabling GLP studies expected by end of 2021.
- Received up to $2.6M award from Cystic Fibrosis Foundation for oral ribosome modulating agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/0001104659-21-106641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/tm2125273d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-106641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer